Pazopanib-induced Endothelial Injury with Podocyte Changes

Pazopanib has been reported to induce proteinuria; however, no pathological findings have been reported. We herein report the case of a 31-year-old man with rhabdomyosarcoma treated with pazopanib who developed nephrotic syndrome. A renal biopsy revealed endothelial injury with podocyte changes. Bas...

Descripción completa

Detalles Bibliográficos
Autores principales: Maruyama, Keisuke, Nakagawa, Naoki, Suzuki, Ayana, Kabara, Maki, Matsuki, Motoki, Shindo, Motohiro, Ogawa, Yayoi, Hasebe, Naoyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5919858/
https://www.ncbi.nlm.nih.gov/pubmed/29269661
http://dx.doi.org/10.2169/internalmedicine.9576-17
Descripción
Sumario:Pazopanib has been reported to induce proteinuria; however, no pathological findings have been reported. We herein report the case of a 31-year-old man with rhabdomyosarcoma treated with pazopanib who developed nephrotic syndrome. A renal biopsy revealed endothelial injury with podocyte changes. Based on the biopsy findings, we diagnosed the patient with nephrotic syndrome caused by pazopanib. Following the discontinuation of pazopanib, the patient's proteinuria gradually decreased without any specific treatment. We should be careful when encountering drug-induced proteinuria in patients taking pazopanib.

Ejemplares similares